{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:07:16Z","timestamp":1793704036179,"version":"4.5.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["34,37"],"award-info":[{"award-number":["34,37"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021068","name":"Universidad de Las Am\u00e9ricas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127598","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T18:03:31Z","timestamp":1754762611000},"page":"127598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Current and emerging Mpox vaccine strategies: A comprehensive review"],"prefix":"10.1016","volume":"62","author":[{"given":"Esteban","family":"Ortiz-Prado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos C.","family":"Kyriakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Vasconez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Pazmi\u00f1o-Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Barriga-Collantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Paz","family":"Cadena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Reascos-Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Acosta-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C.","family":"Acosta-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Izquierdo-Condoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127598_bb0005","doi-asserted-by":"crossref","first-page":"14881","DOI":"10.3390\/ijerph192214881","article-title":"Monkeypox mysteries of the new outbreak in non-endemic areas","volume":"19","author":"Antunes","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2025.127598_bb0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/tropicalmed7100264","article-title":"Global outbreak of human Monkeypox in 2022: update of epidemiology","volume":"7","author":"Ilic","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127598_bb0015","article-title":"Monkeypox virus outbreaks in the African continent: a new zoonotic alert \u2013 correspondence","volume":"108","author":"Saravanan","year":"2022","journal-title":"Int J Surg Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127598_bb0020","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2387442","article-title":"Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity","volume":"13","author":"Liu","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127598_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1005955","article-title":"Monkeypox 2022 outbreak in non-endemic countries: Open questions relevant for public health, nonpharmacological intervention and literature review","volume":"12","author":"Capobianchi","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/vaccines10091419","article-title":"Preventing the next pandemic: is live vaccine efficacious against Monkeypox, or is there a need for killed virus and mRNA vaccines?","volume":"10","author":"Abdelaal","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmmb.2024.100704","article-title":"Human monkeypox virus: a systematic critical review during the pandemic peak","volume":"51","author":"Derhab","year":"2024","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmii.2023.12.006","article-title":"Monkeypox: an outbreak of a rare viral disease","volume":"57","author":"Luo","year":"2024","journal-title":"J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi"},{"key":"10.1016\/j.vaccine.2025.127598_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.985450","article-title":"Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques- a bioinformatics and immunoinformatics approach","volume":"13","author":"Aiman","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2023-001266","article-title":"Mpox gastrointestinal manifestations: a systematic review","volume":"11","author":"Ramakrishnan","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0055","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1038\/s41598-024-58147-y","article-title":"Dynamics of Mpox infection in Nigeria: a systematic review and meta-analysis","volume":"14","author":"Cadmus","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127598_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100527","article-title":"Assessment of the knowledge, attitude, and perception of the world\u2019s population towards monkeypox and its vaccines: a systematic review and descriptive analysis of cross-sectional studies","volume":"20","author":"Tanashat","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2025.127598_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygeno.2023.110763","article-title":"Genome analysis of the mpox (formerly monkeypox) virus and characterization of core\/variable regions","volume":"116","author":"Yu","year":"2024","journal-title":"Genomics"},{"key":"10.1016\/j.vaccine.2025.127598_bb0070","series-title":"Fire-footed rope squirrels (Funisciurus pyrropus) are a reservoir host of monkeypox virus (Orthopoxvirus monkeypox)","author":"Leendertz","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127598_bb0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/d41586-025-00990-8","article-title":"An animal source of mpox emerges \u2014 and it\u2019s a squirrel","volume":"640","author":"Qiu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127598_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030406","article-title":"Human monkeypox virus: an updated review","volume":"101","author":"Adnan","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2025.127598_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.198932","article-title":"The virology of human monkeypox virus (hMPXV): a brief overview","volume":"322","author":"Lansiaux","year":"2022","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2025.127598_bb0090","doi-asserted-by":"crossref","unstructured":"Miranda MD, Caldas GC, Ferreira VN, et al. Monkeypox (Mpox) virus isolation and ultrastructural characterisation from a Brazilian human sample case. Mem Inst Oswaldo Cruz; 118: e230090.","DOI":"10.1590\/0074-02760230090"},{"key":"10.1016\/j.vaccine.2025.127598_bb0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(22)02075-X","article-title":"Monkeypox","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127598_bb0100","unstructured":"Moore MJ, Rathish B, Zahra F. Mpox (Monkeypox). In: StatPearls. Treasure Island (FL): StatPearls Publishing, http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574519\/ (2024, accessed 13 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2508","article-title":"Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: a systematic review and meta-analysis","volume":"34","author":"Cho","year":"2024","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0110","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/vaccines11111708","article-title":"Systematic review on the efficacy, effectiveness, safety, and immunogenicity of Monkeypox vaccine","volume":"11","author":"Ghazy","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002731","article-title":"Infection prevention and control measures to reduce the transmission of mpox: a systematic review","volume":"4","author":"Kuehn","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.vaccine.2025.127598_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1504154","article-title":"Clade Ib: a new emerging threat in the Mpox outbreak","volume":"15","author":"Srivastava","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0125","doi-asserted-by":"crossref","unstructured":"Americo JL, Earl PL, Moss B. Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model. Proc Natl Acad Sci USA; 120: e2220415120.","DOI":"10.1073\/pnas.2220415120"},{"key":"10.1016\/j.vaccine.2025.127598_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/tropicalmed8020076","article-title":"Mpox, caused by the MPXV of the clade IIb lineage, Goes Global","volume":"8","author":"Gao","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127598_bb0135","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1038\/s41467-024-51737-4","article-title":"Evolutionary trajectory and characteristics of Mpox virus in 2023 based on a large-scale genomic surveillance in Shenzhen, China","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127598_bb0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.virol.2012.08.044","article-title":"Orthopoxvirus species and strain differences in cell entry","volume":"433","author":"Bengali","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127598_bb0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/pathogens12030363","article-title":"Orthopoxvirus Zoonoses\u2014do we still remember and are ready to fight?","volume":"12","author":"Giery\u0144ska","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2025.127598_bb0150","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","article-title":"A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease","volume":"187","author":"Zuiani","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127598_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127598_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004904","article-title":"Extracellular Virions: the advance guard of poxvirus infections","volume":"11","author":"Pickup","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2025.127598_bb0165","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/v14102155","article-title":"Monkeypox: a comprehensive review","volume":"14","author":"Harapan","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127598_bb0170","unstructured":"McLean JR, Zucker JE, Vail RM, et al. Prevention and Treatment of Mpox. Baltimore (MD): Johns Hopkins University, http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603707\/ (2024, accessed 5 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0175","series-title":"Tecovirimat is safe but ineffective as treatment for clade II mpox | National Institutes of Health (NIH)","author":"NIH","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127598_bb0180","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJMoa2412439","article-title":"Tecovirimat for clade I MPXV infection in the Democratic Republic of Congo","volume":"392","author":"The PALM007 Writing Group","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127598_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1149909","article-title":"Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis","volume":"14","author":"Shamim","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0190","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMoa2215201","article-title":"Vaccine effectiveness of JYNNEOS against Mpox disease in the United States","volume":"388","author":"Deputy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127598_bb0195","series-title":"Mpox: Vaccines","author":"World Health Organization","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127598_bb0200","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1016\/j.vaccine.2016.11.015","article-title":"Vaccination of special populations: protecting the vulnerable","volume":"34","author":"Doherty","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127598_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2025.127598_bb0215","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2105\/AJPH.2012.301075","article-title":"Measles vaccination before the measles-mumps-rubella vaccine","volume":"103","author":"Hendriks","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2025.127598_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2015.00269","article-title":"Vaccines through centuries: major cornerstones of Global Health","volume":"3","author":"Hajj Hussein","year":"2015","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2025.127598_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877845","article-title":"Prospects on repurposing a live attenuated vaccine for the control of unrelated infections","volume":"13","author":"Seo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-0716-0795-4_17","article-title":"Attenuation methods for live vaccines","volume":"2183","author":"Hajra","year":"2021","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"10.1016\/j.vaccine.2025.127598_bb0235","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0240","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/vaccines9121490","article-title":"Vaccine technologies and platforms for infectious diseases: current Progress, challenges, and opportunities","volume":"9","author":"Ghattas","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127598_bb0250","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/pharmaceutics13020140","article-title":"Strategies for vaccination: conventional vaccine approaches versus new-generation strategies in combination with adjuvants","volume":"13","author":"Bouazzaoui","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.127598_bb0255","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.2671","article-title":"Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy","volume":"42","author":"Bemben","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.vaccine.2025.127598_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.917732","article-title":"Effectiveness and cost-effectiveness of inactivated vaccine to address COVID-19 pandemic in China: evidence from randomized control trials and real-world studies","volume":"10","author":"Fu","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2025.127598_bb0265","first-page":"45","article-title":"Inactivated viral vaccines","author":"Sanders","year":"2014","journal-title":"Vaccine Anal Strateg Princ Control"},{"key":"10.1016\/j.vaccine.2025.127598_bb0270","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/vaccines11091420","article-title":"A subunit vaccine candidate composed of Mpox virus A29L, M1R, A35R, and B6R elicits robust immune response in mice","volume":"11","author":"Yang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1359475","article-title":"NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines","volume":"15","author":"Mai","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106156","article-title":"Progress and prospects on vaccine development against monkeypox infection","volume":"180","author":"Saadh","year":"2023","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2025.127598_bb0285","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1073\/pnas.1819612116","article-title":"On the mechanisms of conjugate vaccines","volume":"116","author":"Rappuoli","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127598_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0295","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/vaccines11030695","article-title":"The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development","volume":"11","author":"Kozak","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0300","first-page":"1","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.127598_bb0305","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/v14040759","article-title":"Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena","volume":"14","author":"Chavda","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127598_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34927","article-title":"Viral vector- and virus-like particle-based vaccines against infectious diseases: a minireview","volume":"10","author":"Henr\u00edquez","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.vaccine.2025.127598_bb0320","first-page":"1","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.127598_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0330","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s00203-023-03480-5","article-title":"Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)","volume":"205","author":"Baghban","year":"2023","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114142","article-title":"Toward rational vaccine engineering","volume":"183","author":"Vishweshwaraiah","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2025.127598_bb0340","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2025.127598_bb0345","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/vaccines12010071","article-title":"DNA vaccines: their formulations","volume":"12","author":"Kozak","year":"2024","journal-title":"Engineering and Delivery Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0350","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/v13020258","article-title":"The key role of nucleic acid vaccines for one health","volume":"13","author":"Fomsgaard","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127598_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.633776","article-title":"A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40290-021-00417-5","article-title":"Delivery strategies for mRNA vaccines","volume":"36","author":"Ramachandran","year":"2022","journal-title":"Pharm Med"},{"key":"10.1016\/j.vaccine.2025.127598_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-4632.2004.02568.x","article-title":"Complications of the smallpox vaccine","volume":"44","author":"Schwartz","year":"2005","journal-title":"Int J Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2025.127598_bb0370","first-page":"S31","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127598_bb0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: the new smallpox vaccine for United States strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.vaccine.2025.127598_bb0380","series-title":"FDA Roundup: August 30, 2024","author":"Office of the Commissioner","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127598_bb0385","unstructured":"Drugs.com. Smallpox vaccine (Dryvax) Use During Pregnancy. Drugs.com, https:\/\/www.drugs.com\/pregnancy\/smallpox-vaccine.html#ref_pregnancy (2024, accessed 4 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0390","series-title":"Vaccines | Smallpox | CDC","author":"CDC","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127598_bb0395","author":"FDA"},{"key":"10.1016\/j.vaccine.2025.127598_bb0400","series-title":"ACAM2000 (Smallpox Vaccine) Questions and Answers","author":"Center for Biologics Evaluation and Research","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127598_bb0405","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/JS9.0000000000000142","article-title":"Monkeypox (Mpox) vaccines and their side effects: the other side of the coin","volume":"109","author":"Sah","year":"2023","journal-title":"Int J Surg Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127598_bb0410","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/ije\/17.3.643","article-title":"The transmission potential of Monkeypox virus in human populations","volume":"17","author":"Pem","year":"1988","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0415","unstructured":"Jezek Z, Grab B, Szczeniowski M, et al. Human monkeypox: secondary attack rates. Bull World Health Organ; 66, https:\/\/pubmed.ncbi.nlm.nih.gov\/2844429\/ (1988, accessed 4 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0420","series-title":"Emergency Use Authorization","author":"Office of the Commissioner","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127598_bb0425","author":"CDC"},{"key":"10.1016\/j.vaccine.2025.127598_bb0430","author":"CDC"},{"key":"10.1016\/j.vaccine.2025.127598_bb0435","series-title":"WHO prequalifies the first vaccine against mpox","author":"WHO","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127598_bb0440","doi-asserted-by":"crossref","first-page":"118","DOI":"10.46234\/ccdcw2024.025","article-title":"The current state and Progress of Mpox vaccine research","volume":"6","author":"Wang","year":"2024","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.vaccine.2025.127598_bb0445","unstructured":"CDC. Mpox Vaccine Recommendations. Centers for Disease Control and Prevention, https:\/\/www.cdc.gov\/poxvirus\/mpox\/vaccines\/vaccine-recommendations.html (2024, accessed 4 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0450","unstructured":"CDC. Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States. Mpox, https:\/\/www.cdc.gov\/mpox\/hcp\/vaccine-considerations\/vaccination-overview.html (2024, accessed 4 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0455","unstructured":"CDC. JYNNEOS Vaccine Effectiveness. Mpox, https:\/\/www.cdc.gov\/mpox\/data-research\/vaccines\/index.html (2024, accessed 4 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0460","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm715152a2","article-title":"Demographic and clinical characteristics of Mpox in persons who had previously received 1 dose of JYNNEOS vaccine and in unvaccinated persons \u2014 29 U.S. Jurisdictions, May 22\u2013September 3, 2022","volume":"71","author":"Farrar","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127598_bb0465","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70069","article-title":"Effectiveness of a single dose of JYNNEOS vaccine in real world: a systematic review and meta-analysis","volume":"7","author":"Taha","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127598_bb0470","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(23)00270-0","article-title":"Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara\u2013Bavaria Nordic vaccine against mpox in children: a national outbreak response","volume":"23","author":"Ladhani","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127598_bb0475","series-title":"News | Bavarian Nordic","author":"Bavarian Nordic","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127598_bb0480","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijid.2020.09.1217","article-title":"MVA-BN as monkeypox vaccine for healthy and immunocompromised","volume":"101","author":"Overton","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127598_bb0485","series-title":"Mpox (previously known as monkeypox) | The Australian Immunisation Handbook","author":"Australian Government","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127598_bb0490","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/vaccines12060651","article-title":"Effectiveness and safety of the MVA\u2013BN vaccine against Mpox in at-risk individuals in the United States (USMVAc)","volume":"12","author":"Back","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0495","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: an attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127598_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105703","article-title":"Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox","volume":"115","author":"Kobiyama","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127598_bb0505","series-title":"WHO adds LC16m8 mpox vaccine to Emergency Use Listing","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127598_bb0510","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/infdis\/jir527","article-title":"Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults","volume":"204","author":"Kennedy","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127598_bb0515","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf074","article-title":"LC16m8 for pre-exposure prophylaxis against Mpox in a high-risk population: an open-label randomized trial","author":"Okumura","year":"2025","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2025.127598_bb0520","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300290","article-title":"Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults","volume":"3","author":"Morino","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.vaccine.2025.127598_bb0525","author":"WHO"},{"key":"10.1016\/j.vaccine.2025.127598_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105974","article-title":"An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge","volume":"230","author":"Li","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.vaccine.2025.127598_bb0535","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/vaccines12070776","article-title":"Enhanced immune responses in mice by combining the Mpox virus B6R-protein and aluminum hydroxide-CpG vaccine adjuvants","volume":"12","author":"Li","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127598_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114269","article-title":"Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus","volume":"43","author":"Ye","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2025.127598_bb0545","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.vaccine.2024.02.027","article-title":"Rapid and highly potent humoral responses to mpox nanovaccine candidates adjuvanted by thermostable scaffolds","volume":"42","author":"Yan","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127598_bb0550","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41590-023-01715-7","article-title":"Rational design of a \u2018two-in-one\u2019 immunogen DAM drives potent immune response against mpox virus","volume":"25","author":"Wang","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0555","doi-asserted-by":"crossref","unstructured":"Chu Q, Huang B, Li M, et al. Non-replicating vaccinia virus NTV as an effective next-generation smallpox and monkeypox vaccine: evidence from mouse and rhesus monkey models. Emerg Microbes Infect; 12: 2278900.","DOI":"10.1080\/22221751.2023.2278900"},{"key":"10.1016\/j.vaccine.2025.127598_bb0560","doi-asserted-by":"crossref","unstructured":"Zeng J, Li Y, Jiang L, et al. Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. Emerg Microbes Infect; 12: 2204151.","DOI":"10.1080\/22221751.2023.2204151"},{"key":"10.1016\/j.vaccine.2025.127598_bb0565","doi-asserted-by":"crossref","unstructured":"Zhang R-R, Wang Z-J, Zhu Y-L, et al. Rational development of multicomponent mRNA vaccine candidates against mpox. Emerg Microbes Infect; 12: 2192815.","DOI":"10.1080\/22221751.2023.2192815"},{"key":"10.1016\/j.vaccine.2025.127598_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29140","article-title":"Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice","volume":"95","author":"Yang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2025.127598_bb0575","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1038\/s41467-023-41628-5","article-title":"mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge","volume":"14","author":"Hou","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127598_bb0580","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.medcli.2023.01.001","article-title":"Vaccines against monkeypox","volume":"160","author":"Reina","year":"2023","journal-title":"Med Clin Engl Ed"},{"key":"10.1016\/j.vaccine.2025.127598_bb0585","unstructured":"WHO. Vaccines and immunization for monkeypox: Interim guidance, 16 November 2022. WHO, https:\/\/www.who.int\/publications\/i\/item\/WHO-MPX-Immunization (accessed 9 October 2024)."},{"key":"10.1016\/j.vaccine.2025.127598_bb0590","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1016\/j.vaccine.2023.07.021","article-title":"Equitable global allocation of monkeypox vaccines","volume":"41","author":"Schaefer","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127598_bb0595","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2025.127598_bb0600","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/MS9.0000000000000550","article-title":"Mpox vaccination in global perspective: priorities and challenges","volume":"85","author":"Rana","year":"2023","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.vaccine.2025.127598_bb0605","doi-asserted-by":"crossref","unstructured":"Press VG, Huisingh-Scheetz M, Arora VM. Inequities in technology contribute to disparities in COVID-19 vaccine distribution. In: JAMA Health Forum. American Medical Association, pp. e210264\u2013e210264.","DOI":"10.1001\/jamahealthforum.2021.0264"},{"key":"10.1016\/j.vaccine.2025.127598_bb0610","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/heq.2021.0177","article-title":"Racial and ethnic disparities in adult vaccination: a review of the state of evidence","volume":"6","author":"Granade","year":"2022","journal-title":"Health Equity"},{"key":"10.1016\/j.vaccine.2025.127598_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-021-00135-5","article-title":"Vaccine market and production capabilities in the Americas","volume":"7","author":"Ortiz-Prado","year":"2021","journal-title":"Trop Dis Travel Med Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:17:56Z","timestamp":1766546276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25008953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":123,"alternative-id":["S0264410X25008953"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127598","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging Mpox vaccine strategies: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127598"}}